ADVERTISEMENT
Dr Cassady Reviews Phase 4 Study Results of Inotuzumab Ozagamicin in R/R ALL
Ryan Cassady, MD, SCCA, discusses the safety and efficacy of low-dose inotuzumab ozagamicin in patients with relapsed or refractory ALL, presented at the 2021 ASH Annual Meeting.
Disclaimer: The views and opinions expressed are those of the author(s) and do not necessarily reflect the official policy or position of Oncology Learning Network or HMP Global, their employees, and affiliates. Any content provided by our bloggers or authors are of their opinion and are not intended to malign any religion, ethnic group, club, association, organization, company, individual, anyone, or anything.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement